Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
5 "Hye-Suk Han"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Impact of Hyperglycemia on Survival and Infection-Related Adverse Events in Patients with Metastatic Colorectal Cancer Who Were Receiving Palliative Chemotherapy
Yong Joo Hong, Hye-Suk Han, Yusook Jeong, Jiwon Jeong, Sung-Nam Lim, Hyung Jin Choi, Hyun-Jung Jeon, Tae-Keun Oh, Sang-Jeon Lee, Ki Hyeong Lee
Cancer Res Treat. 2014;46(3):288-296.   Published online July 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.3.288
AbstractAbstract PDFPubReaderePub
Purpose
Non-metastatic colorectal cancer patients with diabetes have poor overall survival than those without diabetes. However, the effect of hyperglycemia on survival after diagnosis of metastatic colorectal cancer (CRC) has not been assessed. Therefore, we assessed the impact of hyperglycemia on the survival and infection-related adverse events (AEs) in patients with metastatic CRC. Materials and Methods We reviewed the records of 206 patients with newly diagnosed metastatic CRC who were treated with palliative chemotherapy from March 2000 to December 2012 at Chungbuk National University Hospital. The mean glucose level of each patient was calculated using all available glucose results. Results The mean glucose levels ranged between 76.8 and 303.5 mg/dL, and patients were categorized into quartiles in accordance to their mean glucose level: group 1 (< 106.7 mg/dL), group 2 (106.7-117.2 mg/dL), group 3 (117.3-142.6 mg/dL), and group 4 (> 142.6 mg/dL). The median overall survival for patients in groups 1, 2, 3, and 4 were 22.6, 20.1, 18.9, and 17.9 months, respectively; however, this difference was not statistically significant (p=0.643). Compared with patients in group 1, those in groups 2, 3, and 4 were at a higher risk of infection-related AEs, according to a multivariate analysis (p=0.002). Conclusion Hyperglycemia was not associated with shorter survival; however, it was associated with infection-related AEs in patients with newly diagnosed metastatic CRC receiving palliative chemotherapy.

Citations

Citations to this article as recorded by  
  • Glucocorticoid-Induced Hyperglycemia in Oncologic Outpatients: A Narrative Review Using the Quadruple Aim Framework
    Ihab Kandil, Erin Keely
    Canadian Journal of Diabetes.2022; 46(7): 730.     CrossRef
  • Association of Comorbid Diabetes With Clinical Outcomes and Healthcare Utilization in Colorectal Cancer Survivors
    Susan Storey, Zuoyi Zhang, Xiao Luo, Diane Von Ah, Megan Metzger, Jie Zhang, Amrutha Jakka, Kun Huang
    Oncology Nursing Forum.2021; 48(2): 195.     CrossRef
  • The influence on survival of glucocorticoid induced diabetes in cancer patients with metastatic spinal cord compression
    Helga Schultz, Ulrik Pedersen-Bjergaard, Andreas Kryger Jensen, Svend Aage Engelholm, Peter Lommer Kristensen
    Clinical and Translational Radiation Oncology.2018; 11: 19.     CrossRef
  • Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities
    Susan Storey, Diane Ah, Marilyn Hammer
    Oncology Nursing Forum.2017; 44(4): E141.     CrossRef
  • Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors
    Roy E. Strowd, Mackenzie C. Cervenka, Bobbie J. Henry, Eric H. Kossoff, Adam L. Hartman, Jaishri O. Blakeley
    Neuro-Oncology Practice.2015; 2(3): 127.     CrossRef
  • The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors
    Roy E. Strowd, Stuart A. Grossman
    Current Treatment Options in Oncology.2015;[Epub]     CrossRef
  • 12,277 View
  • 72 Download
  • 7 Web of Science
  • 6 Crossref
Close layer
Diagnostic Value of Circulating Extracellular miR-134, miR-185, and miR-22 Levels in Lung Adenocarcinoma-Associated Malignant Pleural Effusion
Yoon Mi Shin, Jieun Yun, Ok-Jun Lee, Hye-Suk Han, Sung-Nam Lim, Jin Young An, Ki Hyeong Lee, Ki Man Lee, Kang Hyeon Choe
Cancer Res Treat. 2014;46(2):178-185.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.178
AbstractAbstract PDFPubReaderePub
Purpose

The accurate and timely diagnosis of malignant pleural effusion (MPE) in lung cancer patients is important because MPE has a poor prognosis and is classified as stage IV disease. Molecular biomarkers for pleural effusion, such as circulating extracellular microRNAs (miRNAs) isolated from pleural fluid, may help in the diagnosis of MPE. The present study examined whether miRNAs that are deregulated in lung cancer (miR-134, miR-185, and miR-22) can serve as diagnostic markers for lung adenocarcinoma-associated MPE (LA-MPE).

Materials and Methods

Real-time reverse transcription quantitative polymerase chain reaction was used to measure the expression of the three miRNAs in samples from 87 patients with pleural effusion comprising 45 LA-MPEs and 42 benign pleural effusions (BPEs). The area under the receiver operating characteristic curve (AUC) was then used to evaluate the diagnostic performance of each of the three miRNAs and compare it with that of the common tumor marker, carcinoembryonic antigen (CEA).

Results

The expression of all three miRNAs was significantly lower in LA-MPE than in BPE (p <0.001). The AUCs for miR-134, miR-185, miR-22, and CEA were 0.721, 0.882, 0.832, and 0.898, respectively. Combining CEA with the three miRNAs increased the diagnostic performance, yielding an AUC of 0.942 (95% confidence interval, 0.864 to 0.982), with a sensitivity of 91.9% and a specificity of 92.5%.

Conclusion

The present study suggests that the expression levels of circulating extracellular miR-134, miR-185, and miR-22 in patients with pleural effusion may have diagnostic value when differentiating between LA-MPE and BPE.

Citations

Citations to this article as recorded by  
  • Key methodological challenges in detecting circulating miRNAs in different biofluids
    Chitra Mestry, Tester F Ashavaid, Swarup AV Shah
    Annals of Clinical Biochemistry: International Journal of Laboratory Medicine.2023; 60(1): 14.     CrossRef
  • MiRNAs in Lung Adenocarcinoma: Role, Diagnosis, Prognosis, and Therapy
    Yongan Song, Leonardo Kelava, István Kiss
    International Journal of Molecular Sciences.2023; 24(17): 13302.     CrossRef
  • High Diagnostic and Prognostic Value of miRNAs Compared with the Carcinoembryonic Antigen As A Traditional Tumor Marker
    Neda Yaghoubi , Farnaz Zahedi Avval , Majid Khazaei, Amirhossein Sahebkar , Seyed Hamid Aghaee-Bakhtiari
    Anti-Cancer Agents in Medicinal Chemistry.2022; 22(2): 206.     CrossRef
  • Diagnostic utility of pleural cell-free nucleic acids in undiagnosed pleural effusions
    Wen Zhao, Xi-Shan Cao, Yu-Ling Han, Xu-Hui Wen, Wen-Qi Zheng, Zhi-De Hu
    Clinical Chemistry and Laboratory Medicine (CCLM).2022; 60(10): 1518.     CrossRef
  • Construction and analysis of expression profile of exosomal lncRNAs in pleural effusion in lung adenocarcinoma
    Xiaolu Huang, Huixin Zhou, Xiang Yang, Wenjing Shi, Lijuan Hu, Junjun Wang, Fan Zhang, Fanggui Shao, Meijuan Zhang, Feng Jiang, Yumin Wang
    Journal of Clinical Laboratory Analysis.2022;[Epub]     CrossRef
  • Molecular testing on serous effusions
    Ben Davidson
    Diagnostic Cytopathology.2021; 49(5): 640.     CrossRef
  • Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions
    Maria Alba Sorolla, Anabel Sorolla, Eva Parisi, Antonieta Salud, José M. Porcel
    Cancers.2021; 13(11): 2798.     CrossRef
  • Four plasma miRNAs act as biomarkers for diagnosis and prognosis of non‑small cell lung cancer
    He-Guo Jiang, Chun-Hua Dai, Ya-Ping Xu, Qian Jiang, Xian-Bin Xia, Yang Shu, Jian Li
    Oncology Letters.2021;[Epub]     CrossRef
  • Molecular testing on serous effusion: An update
    Saumya Sahu, Parikshaa Gupta, Pranab Dey
    Cytojournal.2021; 18: 35.     CrossRef
  • Non-coding RNA and lung cancer progression
    Afeez Adekunle Ishola, Anita Silas La’ah, Hung Dinh Le, Viet Quoc Nguyen, Yi-Ping Yang, Shih-Jie Chou, Hsiao-Yun Tai, Chian-Shiu Chien, Mong-Lien Wang
    Journal of the Chinese Medical Association.2020; 83(1): 8.     CrossRef
  • Role of microRNAs as Clinical Cancer Biomarkers for Ovarian Cancer: A Short Overview
    Cristina Elena Staicu, Dragoș-Valentin Predescu, Călin Mircea Rusu, Beatrice Mihaela Radu, Dragos Cretoiu, Nicolae Suciu, Sanda Maria Crețoiu, Silviu-Cristian Voinea
    Cells.2020; 9(1): 169.     CrossRef
  • microRNA exchange via extracellular vesicles in cancer
    Luyen Tien Vu, Jinhua Gong, Thach Tuan Pham, Yeokyeong Kim, Minh T. N. Le
    Cell Proliferation.2020;[Epub]     CrossRef
  • MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions
    Kimberly A. Birnie, Cecilia M. Prêle, Arthur W. (Bill) Musk, Nicholas de Klerk, Y. C. Gary Lee, Deirdre Fitzgerald, Richard J. N. Allcock, Philip J. Thompson, Jenette Creaney, Bahareh Badrian, Steven E. Mutsaers
    Disease Markers.2019; 2019: 1.     CrossRef
  • Combination of DNA ploidy analysis and miR-21 or miR-24 in screening malignant pleural effusion
    Chongmei Liu, Liuyan Huang, Xuechun Zhang, Juan Yang
    Interactive CardioVascular and Thoracic Surgery.2018; 26(3): 376.     CrossRef
  • Microarray expression profile and analysis of circular RNA regulatory network in malignant pleural effusion
    Yakun Wen, Yong Wang, Zhenchuan Xing, Zongjian Liu, Ziliang Hou
    Cell Cycle.2018; 17(24): 2819.     CrossRef
  • Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis
    Mei Feng, Jing Zhu, Liqun Liang, Ni Zeng, Yanqiu Wu, Chun Wan, Yongchun Shen, Fuqiang Wen
    International Journal of Clinical Oncology.2017; 22(2): 283.     CrossRef
  • miR-134: A Human Cancer Suppressor?
    Jing-Yu Pan, Feng Zhang, Cheng-Cao Sun, Shu-Jun Li, Guang Li, Feng-Yun Gong, Tao Bo, Jing He, Rui-Xi Hua, Wei-Dong Hu, Zhan-Peng Yuan, Xin Wang, Qi-Qiang He, De-Jia Li
    Molecular Therapy - Nucleic Acids.2017; 6: 140.     CrossRef
  • Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review)
    Jingyu Wang, Yuan Li, Meiman Ding, Honghe Zhang, Xiaoming Xu, Jinlong Tang
    International Journal of Oncology.2017; 50(2): 345.     CrossRef
  • MicroRNA-134 modulates glioma cell U251 proliferation and invasion by targeting KRAS and suppressing the ERK pathway
    Yuguang Zhao, Dong Pang, Cui Wang, Shijiang Zhong, Shuang Wang
    Tumor Biology.2016; 37(8): 11485.     CrossRef
  • MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features
    Ruma Dey Ghosh, Sangeeta Ghuwalewala, Pijush Das, Sapan Mandloi, Sk Kayum Alam, Jayanta Chakraborty, Sajal Sarkar, Saikat Chakrabarti, Chinmoy Kumar Panda, Susanta Roychoudhury
    Scientific Reports.2016;[Epub]     CrossRef
  • Cell‐free microRNAs in blood and other body fluids, as cancer biomarkers
    Blanca Ortiz‐Quintero
    Cell Proliferation.2016; 49(3): 281.     CrossRef
  • Clinical relevance of circulating cell-free microRNAs in ovarian cancer
    Koji Nakamura, Kenjiro Sawada, Akihiko Yoshimura, Yasuto Kinose, Erika Nakatsuka, Tadashi Kimura
    Molecular Cancer.2016;[Epub]     CrossRef
  • MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma
    Ling Chen, Guangming Kong, Chuantao Zhang, Hongyan Dong, Cuicui Yang, Guanhua Song, Chengye Guo, Lin Wang, Hongsheng Yu
    Oncotarget.2016; 7(15): 20041.     CrossRef
  • Hepatocellular carcinoma and microRNA: New perspectives on therapeutics and diagnostics
    Ningning Yang, Nsikak R. Ekanem, Clement A. Sakyi, Sidhartha D. Ray
    Advanced Drug Delivery Reviews.2015; 81: 62.     CrossRef
  • Reduced expression of microRNA-134 correlates with malignancy and poor prognosis in human glioma
    Jianfeng Zhong, Bing Li
    Journal of Clinical Neuroscience.2015; 22(3): 583.     CrossRef
  • 2015 update on the diagnosis and management of neoplastic pericardial disease
    Chiara Lestuzzi, Massimiliano Berretta, Witold Tomkowski
    Expert Review of Cardiovascular Therapy.2015; 13(4): 377.     CrossRef
  • Extracellular microRNAs in bronchoalveolar lavage samples from patients with lung diseases as predictors for lung cancer
    Grit Rehbein, Bernd Schmidt, Michael Fleischhacker
    Clinica Chimica Acta.2015; 450: 78.     CrossRef
  • 16,417 View
  • 138 Download
  • 38 Web of Science
  • 27 Crossref
Close layer
Case Reports
Multiple Cardiac Metastases from a Nonfunctioning Pancreatic Neuroendocrine Tumor
Yong Hyeok Choi, Hye-Suk Han, Sung-Nam Lim, Sang Yeub Lee, Ji Hae Koo, Ok-Jun Lee, Ki Hyeong Lee, Seung Taik Kim
Cancer Res Treat. 2013;45(2):150-154.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.150
AbstractAbstract PDFPubReaderePub
Pancreatic neuroendocrine tumors (pNETs) are rare neoplasms, which most commonly metastasize to the liver. However, intrathoracic metastases from pNETs are encountered infrequently. This report describes a case of nonfunctioning pNET with multiple cardiac metastases. A 56-year-old male presented with a palpable abdominal mass that showed progressive enlargement. Findings on computed tomography (CT) of the abdomen revealed two relatively well-marginated inhomogeneous low-attenuation masses, one in the head of the pancreas and the other in the tail. Multiple enhancing masses in the left pericardium with myocardial involvement were observed on chest CT and transthoracic echocardiography. Needle biopsies were performed on the mass in the tail of the pancreas and the left ventricular apical pericardium; histologic examination by hematoxylin and eosin morphology and immunohistochemical staining showed pNET in both. This is the first report of pNET with multiple cardiac metastases to previously undescribed metastatic sites.

Citations

Citations to this article as recorded by  
  • Cardiac Neuroendocrine Tumor Metastases on68Ga-DOTATATE PET/CT: Identification and Prognostic Significance
    Hwan Lee, Ahmad S. Alhamshari, Vandan Patel, Abhijit Bhattaru, Chaitanya Rojulpote, Mahesh K. Vidula, Daniel A. Pryma, Paco E. Bravo
    Journal of Nuclear Medicine.2024; 65(11): 1745.     CrossRef
  • Atypical Cardiac Location of Melanoma of Unknown Origin
    Agnieszka Styczeń, Mariusz Kozak, Marta Karaś-Głodek, Elżbieta Czekajska-Chehab, Andrzej Tomaszewski, Andrzej Wysokiński, Tomasz Zapolski
    Medicina.2021; 57(2): 107.     CrossRef
  • Cardiac Metastases in Patients with Neuroendocrine Tumours: Clinical Features, Therapy Outcomes, and Prognostic Implications
    Man Liu, Eleni Armeni, Shaunak Navalkissoor, Joseph Davar, Luke Sullivan, Charlotte Leigh, Luke Furtado O’Mahony, Aimee Hayes, Dalvinder Mandair, Jie Chen, Martyn Caplin, Christos Toumpanakis
    Neuroendocrinology.2021; 111(10): 907.     CrossRef
  • A concealed carcinoid cardiac metastasis uncovered by comprehensive cardiovascular magnetic resonance-based tissue characterization: a case report
    Georgios Georgiopoulos, Panagiota Mitropoulou, Pier Giorgio Masci, Juerg Schwitter, Khan Tina, Voges Inga, Raisi Estabragh Zahra, Minguito Carazo Carlos, Thomson Ross
    European Heart Journal - Case Reports.2020; 4(6): 1.     CrossRef
  • A Multimodal Approach to Evaluate for Cardiac Metastasis in a Case of Non-Small Cell Lung Cancer
    Nadeem Bilani, Leah Elson, Felipe Martinez, Diego Sadler, Zeina Nahleh, Elizabeth Elimimian, Evan Alley
    Case Reports in Oncology.2020; 13(1): 212.     CrossRef
  • Identification of multiple cardiac metastases from nonsmall-cell lung cancer by 18F-FDG PET/CT
    Shengming Deng, Bin Zhang, Jihui Li, Shibiao Sang, Wei Zhang
    Medicine.2018; 97(49): e12868.     CrossRef
  • 12,376 View
  • 67 Download
  • 6 Crossref
Close layer
Poorly Differentiated Neuroendocrine Carcinoma in a Perigastric Lymph Node from an Unknown Primary Site
Hee Seung Lee, Hye-Suk Han, Sung-Nam Lim, Hyun-Jung Jeon, Ho-chang Lee, Ok-Jun Lee, Hyo Young Yun, Ki Hyeong Lee, Seung Taik Kim
Cancer Res Treat. 2012;44(4):271-274.   Published online December 31, 2012
DOI: https://doi.org/10.4143/crt.2012.44.4.271
AbstractAbstract PDFPubReaderePub
Neuroendocrine carcinomas from an unknown primary site are uncommon. The authors report on a case of neuroendocrine carcinoma in a perigastric lymph node (LN) with no primary site. A 52-year-old male patient with early gastric adenocarcinoma underwent treatment by endoscopic submucosal dissection, and, six months later, findings on a computed tomographic scan of the abdomen revealed a LN enlargement measuring 2.0 cm in the perigastric region. The patient underwent subtotal gastrectomy and regional LN dissection under a suggestive preoperative diagnosis of gastric adenocarcinoma with LN metastasis. However, microscopically, no residual tumor was found in the stomach, and the perigastric LN showed poorly differentiated neuroendocrine carcinoma (PDNEC). After an extensive workup, no primary site was identified. The patient also received four cycles of etoposide and cisplatin. Despite its extremely rare incidence, this case suggests that PDNEC of an unknown primary site is limited to a single site, and that resection should be considered in combination with chemotherapy.

Citations

Citations to this article as recorded by  
  • A case of laparoscopic lymphadenectomy for adenocarcinoma of unknown primary incidentally detected as a solitary enlarged lymph node along the common hepatic artery
    Tomonori Morimoto, Shigeo Hisamori, Hiromitsu Kinoshita, Yosuke Yamada, Yuki Teramoto, Takashi Sakamoto, Keiko Kasahara, Shintaro Okumura, Tatsuto Nishigori, Shigeru Tsunoda, Kazutaka Obama
    Surgical Case Reports.2024;[Epub]     CrossRef
  • Synchronous Gastric Adenocarcinoma and Perigastric Lymph Node Metastatic Squamous Cell Carcinoma with Unknown Primary: A Case Report
    Bernard K Seshie, Ki Hyun Kim, Hyun Jung Lee, Si Hak Lee, Sun-Hwi Hwang
    The Journal of Minimally Invasive Surgery.2020; 23(2): 99.     CrossRef
  • Metastatic Neuroendocrine Carcinoma of Unknown Origin Arising in the Femoral Nerve Sheath
    Nicholas Candy, Adam Young, Kieren Allinson, Oliver Carr, Jason McMillen, Rikin Trivedi
    World Neurosurgery.2017; 104: 1047.e1.     CrossRef
  • Submucosal small-cell neuroendocrine carcinoma of the larynx detected using 18F-fluorodeoxyglucose positron emission tomography/computed tomography: A case report and review of the literature
    HONG-FANG YING, YANG-YANG BAO, SHUI-HONG ZHOU, LIANG CHAI, KUI ZHAO, TING-TING WU
    Oncology Letters.2014; 8(3): 1065.     CrossRef
  • 11,489 View
  • 49 Download
  • 4 Crossref
Close layer
Metastatic Renal Cell Carcinoma in a Supraclavicular Lymph Node with No Known Primary: A Case Report
Young-Rak Choi, Hye-Suk Han, Ok-Jun Lee, Sung-Nam Lim, Mi-Jin Kim, Myeong-Ho Yeon, Hyun-Jung Jeon, Ki Hyeong Lee, Seung Taik Kim
Cancer Res Treat. 2012;44(3):215-218.   Published online September 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.3.215
AbstractAbstract PDFPubReaderePub
Although metastasis is relatively frequent in cases of renal cell carcinoma (RCC), metastasis in the cervical or supraclavicular lymph node (LN) is relatively rare. Moreover, cases of metastatic RCC with a non-identifiable kidney mass are extremely rare. Here, the authors report a case of metastatic RCC in a supraclavicular LN without a primary kidney lesion. A 69-year-old man presented with a progressively enlarging right supraclavicular mass. Incisional biopsy of the affected supraclavicular LN was performed, and histological examination revealed metastatic RCC. However, no tumor was found in either kidney, despite various examinations. The patient was treated with radiotherapy followed by sunitinib. After three months on sunitinib, a follow-up computed tomography scan revealed that the supraclavicular LN had markedly decreased, and after 20 months, the disease had not progressed. This case suggests that, even when there is no primary kidney lesion, clinicians must consider the possibility of metastatic RCC when evaluating patients with clear cell carcinoma with an unknown primary site.

Citations

Citations to this article as recorded by  
  • The Relevance of the Virchow Node and Virchow Triad in Renal Cancer Diagnosis
    Luiza-Roxana Dorobantu-Lungu, Viviana Dinca, Andrei Gegiu, Dan Spataru, Andreea Toma, Luminita Welt, Mihaela Florentina Badea, Constantin Caruntu, Cristian Scheau, Ilinca Savulescu-Fiedler
    Clinics and Practice.2025; 15(1): 18.     CrossRef
  • Pure Metastatic Papillary Renal Cell Carcinoma Without Renal Mass: A Case Report and Literature Review
    Pay Enes, Ibrahim Hacibey, Serhat Yentur, Salih Sonmez, Atilla Semercioz
    International Journal of Clinical and Experimental Medical Sciences.2024; 10(2): 25.     CrossRef
  • Nivolumab rechallenge after severe immune hepatitis in a metastatic renal cell cancer patient with hepatitis B and no detectable primary
    Lutfiye Demir, Funda Canaz
    Indian Journal of Cancer.2023; 60(1): 114.     CrossRef
  • Extrarenal renal cell carcinoma arising in the kidney proximity but without an identifiable renal primary – an intriguing dilemma: report of three cases and review of the literature
    Mehdi Mansoor, Morgan Young‐Speirs, Bing Ren, Geoffrey Gotto, Larissa Merten, Summit Sawhney, Farshid Siadat, Andres M Acosta, Abbas Agaimy, Kiril Trpkov
    Histopathology.2022; 81(5): 635.     CrossRef
  • New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
    Elie Rassy, Pauline Parent, Felix Lefort, Stergios Boussios, Giulia Baciarello, Nicholas Pavlidis
    Critical Reviews in Oncology/Hematology.2020; 147: 102882.     CrossRef
  • Metastatic renal cell carcinoma of unknown primary site. Clinical follow-up
    N. A. Ognerubov, T. S. Antipova, G. E. Gumareva
    Journal of Modern Oncology.2020; 22(3): 149.     CrossRef
  • Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature
    Anders Overby, Lone Duval, Morten Ladekarl, Britt Elmedal Laursen, Frede Donskov
    Clinical Genitourinary Cancer.2019; 17(1): e32.     CrossRef
  • Central pancreatectomy in portal annular pancreas for metastatic renal cell carcinoma: a case report
    Hiroshi Yamaguchi, Yasutoshi Kimura, Minoru Nagayama, Masafumi Imamura, Shingo Tanaka, Makoto Yoshida, Eiji Yoshida, Hiroki Fujino, Takashi Machiki, Koji Miyanishi, Toru Mizuguchi, Junji Kato, Ichiro Takemasa
    World Journal of Surgical Oncology.2019;[Epub]     CrossRef
  • Metastatic renal cell carcinoma with undetectable renal mass presenting as lymphadenopathy
    Mohamed Salah Fayaz, Aishah Ebrahim Al-Qaderi, Mustafa Shawki El-Sherify
    CEN Case Reports.2017; 6(1): 36.     CrossRef
  • The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future
    Lisanne C. Hamming, Ben J. Slotman, Henk M. W. Verheul, Victor L. Thijssen
    Angiogenesis.2017; 20(2): 217.     CrossRef
  • Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
    Esther A. Kleibeuker, Matthijs A. ten Hooven, Kitty C. Castricum, Richard Honeywell, Arjan W. Griffioen, Henk M. Verheul, Ben J. Slotman, Victor L. Thijssen
    Cancer Medicine.2015; 4(7): 1003.     CrossRef
  • Combining radiotherapy with sunitinib: lessons (to be) learned
    Esther A. Kleibeuker, Matthijs A. ten Hooven, Henk M. Verheul, Ben J. Slotman, Victor L. Thijssen
    Angiogenesis.2015; 18(4): 385.     CrossRef
  • Sunitinib

    Reactions Weekly.2014; 1494(1): 42.     CrossRef
  • To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma
    Christian Weiss, Björn Schulze, Annette Ottinger, Claus Rödel
    World Journal of Urology.2014; 32(1): 59.     CrossRef
  • 13,454 View
  • 101 Download
  • 14 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP